WebAll patients achieved an R0 resection with a pathologic response rate of 40% and a pathologic complete response (ypCR) rate of 23%. The 2-year progression-free survival and overall survival were 50% and 49.6%, respectively. The recommended phase II dose of everolimus with concurrent weekly carboplatin and radiation is 2.5mg QOD. 展开 WebNeoadjuvant chemotherapy included paclitaxel plus cisplatin (TP group; 62 patients) or paclitaxel plus loplatin (TL group; 58 patients), which were administered three weekly, and cisplatin or loplatin, which were administered weekly for synchronous chemotherapy. External beam radiation therapy (50.4– 56.35 Gy/28 f, 180– 215 cGy/f, 5 f/w ...
PD-L1 blockade in combination with carboplatin as immune …
WebApr 1, 2000 · Weekly carboplatin and paclitaxel given concurrently with definitive once-daily external beam radiation therapy is well tolerated with over 90% of patients completing prescribed therapy. An ultimate CR rate of greater than 70% was obtained, which … WebIn the absence of identified therapeutic targets, chemotherapy is the main systemic treatment option for triple-negative breast cancer (TNBC). The achievement of a pathological complete response (pCR) after neoadjuvant chemotherapy leads to good outcome, whereas patients not achieving a pCR are at high risk of relapse. Various trials … fcsk926
Weekly carboplatin and paclitaxel followed by concomitant …
WebApr 10, 2024 · With a median follow-up of 60 months, 5-year overall survival was 72% adjuvant carboplatin and paclitaxel versus 71% control, and 5-year progression-free survival was 63% versus 61%. Grade >3 adverse events occurred in 81% of the adjuvant carboplatin and paclitaxel group compared with 62% of the control. WebJan 2, 1998 · Our LUN-27 trial of weekly paclitaxel and concurrent radiation for 6 weeks with no adjuvant chemotherapy produced substantial response and survival rates with … WebCARBOplatin is administered once every 7 days concomitantly with radiotherapy for 6 cycles. This treatment is followed by adjuvant chemotherapy consisting of CARBOplatin at AUC 5 intravenously and 5-FU infusion at 1000 mg/m 2 /day by 96h infusion every 4 weeks for a total of three cycles, beginning 4 weeks fcsk913